1947 | Apri | Hiroshi Tsuzuki (CEO) established the company in Tennoji-ku, Osaka with start-up capital of 195,000 yen. | |
---|---|---|---|
July | Injection Product for Neutropenia, "PANILTIN", sales launched | ||
1949 | February | Reishin Tanimura became the President. | |
September | Company head office relocated to Higashi-ku, Osaka. Manufacturing plant relocated to Ashiya-shi, Hyogo. |
||
1951 | June | Agreement for the sole distribution of Senju Products through Takeda Pharmaceutical Company Limited. | |
1955 | December | Masao Yoshida became the President. | |
1958 | December | Ophthalmic Solution for Cataract, "KATALIN", sales launched. | |
1962 | December | Itami Plant established for manufacturing of ingredients in Itami, Hyogo. | |
1965 | April | Artificial Tear Ophthalmic Solution, "MYTEAR", sales launched. | |
May | Company head office relocated to Kita-ku, Osaka | ||
1972 | March | Company head office and Osaka branch are relocated to Hiranomachi, Higashi-ku, Osaka | |
1974 | June | Fukusaki Plant for manufacturing established in Kanzaki-gun, Hyogo | |
June | Shoji Yoshida became the President. | ||
1978 | November | Company head office relocated in Hiranomachi, Higashi-ku, Osaka. | |
1980 | February | Ophthalmic Solution for exclusive use on contact lens, "MYTEAR CL", sales launched | |
1981 | September | Penicillin Antibiotic Ophthalmic Product, "SULPELIN", sales launched | |
1985 | December | Antifungal Ophthalmic Product, "PIMARICIN", sales launched | |
1987 | January | Intraocular Irrigating Solution, "OPEGUARD MA",sales launched. | |
1988 | February | Cephalosporin Antibiotic Ophthalmic Product, "BESTRON", sales launched | |
October | NSAID Ophthalmic Solution, "NIFLAN", sales launched | ||
1993 | January | Established a resident office in California, U.S.A. | |
February | Established Kobe Creative Center | ||
July | Ophthalmic Viscoelastic Preparation, "OPELEAD", sales launched | ||
1997 | April | Celebrated 50th anniversary of company foundation. | |
2000 | July | NSAID Ophthalmic Solution, "BRONUCK", sales launched | |
2001 | April | Established a laboratory in Oregon, U.S.A. | |
2004 | May | Established resident office in Amsterdam, Netherland | |
September | Anti-infective Fluoroquinolone Ophthalmic Solution, "GATIFLO", sales launched | ||
2006 | April | Established a liaison office SENJU USA, INC., in California, U.S.A. Established a resident office in Beijing, China. |
|
June | Yukoh Yoshida became the President. | ||
2008 | May | Established a liaison office Senju Medical Consulting (Shanghai) Co., Ltd., in Shanghai, China. | |
Ophthalmic Suspension for Spring Catarrh, "TALYMUS", sales launched | |||
December | Karatsu Plant for manufacturing established in karatsu-shi, Saga | ||
2009 | October | "LUMIGAN" Ophthalmic Solution 0.03% for treatment of glaucoma and ocular hypertension, sales launched. | |
2010 | November | Established a liaison office SENJU PHARMACEUTICAL SCIENCE & TECHNOLOGY (BEIJING) CO., LTD., in Beijing, China, followed by liquidation in July 2011 of Senju Medical Consulting (Shanghai) Co., Ltd. | |
2011 | November | Established a resident office in Hanoi, Vietnam. | |
2012 | May | "AIPHAGAN" Ophthalmic Solution 0.1% for treatment of glaucoma and ocular hypertension, sales launched. | |
December | Established a resident office in Moscow, Russia. | ||
2017 | April | Celebrated 70th anniversary of company foundation. | |
2018 | February | Completed construction of new corporate building. | |
June | "IBULIEF" I.V. Injection 20 mg for treatment of patent ductus arteriosus in premature infants, sales launched. | ||
August | Established a liaison office Senju Poland Sp. z o.o., in Warsaw, Poland. | ||
2019 | April | Established Kobe Innovative Center. Jiangsu QianShou Pharmaceutical Co., Ltd. in Jiangsu Province, China, became a subsidiary company. |
|
June | Shuhei Yoshida became President. | ||
September | Macrolide antibiotic "AZIMYCIN" Ophthalmic Solution 1% sales launched. | ||
October | Established a limited liability company and liaison office SENJU Pharmaceutical RUS, in Moscow, Russia. | ||
December | "AIBETA" Combination Ophthalmic Solution for treatment of glaucoma and ocular hypertension, sales launched. | ||
2020 | June | "AILAMIDE" Combination Ophthalmic Suspension for treatment of glaucoma and ocular hypertension, sales launched. | |
2021 | December | “Ranibizumab BS Intravitreal Injection Kit 10 mg/mL ‘Senju’” for treatment of nAMD and mCNV, sales launched. | |
2022 | April | Launch of Distribution of Medical Devices | |
2023 | February | Launch of the supplement brand “onoono” |